4 results about "Amniotic stem cells" patented technology

The application discloses an optimized method for preparing amniotic membrane stem cell membrane pieces, relates to the technical field of tissue engineering and regenerative medicine, and significantly shortens the preparation period of the amniotic membrane stem cell membrane pieces by adding nicotinamide adenine dinucleotide (NAD+) and a precursor compound beta-nicotinamide mononucleotide (NMN) in a traditional cell membrane piece culture medium, combining with vitamin C (VC) and a mechanical scratching method. More importantly, the method can effectively reduce the surface expression amount of stem cell CD34 in the membrane pieces, from about 2.04% in a conventional method to below 0.12%, and the prepared stem cell membrane pieces have lower immunogenicity and more definite mesenchymal stem cell characteristics, so that the safety and effectiveness of the stem cell membrane pieces in clinical transplantation application are greatly improved.

This invention provides a method for producing induced pluripotent stem cells. [Solution] The present disclosure includes the step of producing induced pluripotent stem cells by expressing exogenous nucleic acids encoding proteins OCT3 / 4, SOX2, KLF4, LIN28, and L-MYC, as well as p53-shRNA, in umbilical cord amniotic stem cells under conditions suitable for reprogramming stem cells. The present disclosure also includes the induced pluripotent stem cell population obtainable by this method, the induced pluripotent stem cell population obtained by this method, a pharmaceutical composition containing the induced pluripotent stem cells of the present invention, a method for differentiating the induced pluripotent stem cells of the present invention, a pharmaceutical composition containing the differentiated induced pluripotent stem cells obtained by this method, and a method for treating congenital or acquired degenerative disorders in a subject, comprising the step of administering target cells differentiated from pluripotent stem cells to the subject.

Provided herein include methods, compositions, isolated cells, cell models, and kits suitable for use in profiling various cell types in amnion including amnion epithelial cells, amnion mesenchymal cells, fibroblasts, macrophages, as well as amnion stem cells including amnion epithelial stem cells and amnion mesenchymal stem cells. The present disclosure also discloses novel markers for various cell types in human amnion, including marker genes, transcription factors and signaling molecules associated with various stages of amniotic development. The methods, cell models, and gene signatures disclosed herein can be used for a variety of research, diagnostic, or therapeutic applications.

Provided herein include methods, compositions, isolated cells, cell models, and kits suitable for use in profiling various cell types in amnion including amnion epithelial cells, amnion mesenchymal cells, fibroblasts, macrophages, as well as amnion stem cells including amnion epithelial stem cells and amnion mesenchymal stem cells. The present disclosure also discloses novel markers for various cell types in human amnion, including marker genes, transcription factors and signaling molecules associated with various stages of amniotic development. The methods, cell models, and gene signatures disclosed herein can be used for a variety of research, diagnostic, or therapeutic applications.